Key Takeaways
- • Nominee directors appointed by activist investors, private equity firms, and venture capital investors face a fundamental tension between fiduciary duties to protect board confidentiality and investor expectations to share sensitive company information.
- • Delaware and Canadian corporate law differ materially on the permissibility of nominee directors sharing confidential board information with their appointing investors, with a recent Delaware Court of Chancery ruling highlighting these jurisdictional distinctions.
- • Shareholder activism campaigns have maintained elevated levels through 2025, with activists continuing strategic initiatives despite economic and geopolitical uncertainty, making board composition and information governance increasingly critical governance issues.
- • Investors and nominee directors in Canadian market transactions must navigate specific Canadian corporate law requirements governing the disclosure of confidential company information, distinct from U.S. regulatory frameworks.
- • Best practice for appointing nominee directors requires careful documentation of information-sharing protocols, fiduciary obligations, and legal constraints prior to board appointment to mitigate conflicts between investor interests and corporate governance standards.
Summary
Nominee directors—individuals appointed by activist investors, private equity funds, and venture capital firms to represent investor interests on corporate boards—occupy a legally complex position that creates significant tension between their fiduciary duties and investor expectations. The core governance issue centers on whether nominee directors should prioritize the confidentiality of board deliberations or the investor's expectation of receiving sensitive company information to inform investment decisions. This conflict has moved from theoretical to practical importance as shareholder activism activity has remained elevated through 2025, with activists continuing to pursue campaigns and board representation despite macroeconomic headwinds and geopolitical uncertainty.
A recent Delaware Court of Chancery ruling has clarified that Canadian and Delaware corporate law diverge materially on this critical issue, establishing different legal standards for nominee director conduct depending on jurisdiction. The ruling underscores that investors and their appointed directors cannot assume that practices permissible in Delaware will satisfy Canadian corporate law requirements. This jurisdictional variance has immediate implications for cross-border transactions and fund structures that operate in multiple regulatory regimes.
For investors operating in or with assets in the Canadian market, the legal framework governing confidential company information disclosure requires careful attention. Canadian corporate law imposes specific constraints on how nominee directors may share board-level information with their appointing investors, constraints that differ from U.S. practice. These restrictions reflect Canadian jurisprudence on fiduciary duty, board confidentiality, and the proper scope of nominee director obligations.
Practitioners and institutional investors appointing nominee directors should implement detailed governance protocols before board appointments commence. These protocols should address information-sharing permissions, the boundaries of fiduciary confidentiality obligations, and mechanisms for navigating conflicts between investor information rights and corporate governance standards. Written documentation that clearly delineates what information may or may not be shared, the circumstances under which sharing is permissible, and the legal jurisdiction governing those determinations substantially reduces litigation risk and ensures nominee directors understand their obligations. As shareholder activism continues to reshape corporate boardrooms, clarity on nominee director conduct has become a foundational component of responsible activist and private equity investing strategies.
A recent Delaware Court of Chancery ruling has clarified that Canadian and Delaware corporate law diverge materially on this critical issue, establishing different legal standards for nominee director conduct depending on jurisdiction. The ruling underscores that investors and their appointed directors cannot assume that practices permissible in Delaware will satisfy Canadian corporate law requirements. This jurisdictional variance has immediate implications for cross-border transactions and fund structures that operate in multiple regulatory regimes.
For investors operating in or with assets in the Canadian market, the legal framework governing confidential company information disclosure requires careful attention. Canadian corporate law imposes specific constraints on how nominee directors may share board-level information with their appointing investors, constraints that differ from U.S. practice. These restrictions reflect Canadian jurisprudence on fiduciary duty, board confidentiality, and the proper scope of nominee director obligations.
Practitioners and institutional investors appointing nominee directors should implement detailed governance protocols before board appointments commence. These protocols should address information-sharing permissions, the boundaries of fiduciary confidentiality obligations, and mechanisms for navigating conflicts between investor information rights and corporate governance standards. Written documentation that clearly delineates what information may or may not be shared, the circumstances under which sharing is permissible, and the legal jurisdiction governing those determinations substantially reduces litigation risk and ensures nominee directors understand their obligations. As shareholder activism continues to reshape corporate boardrooms, clarity on nominee director conduct has become a foundational component of responsible activist and private equity investing strategies.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.